Glaukos has turned into one of the market’s stronger healthcare stories in 2026, with the share price climbing sharply as investors respond to record sales, index moves and a shift into profitability. With the stock now at US$233.04, the real question for you is whether that price still lines up with the cash flows the business is expected to generate, based on a Discounted Cash Flow (DCF) view of intrinsic value. Glaukos has returned 347.6% over the past 5 years, which puts real weight on...
Motley Fool Press Release.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
Glaukos’ iDose TR Phase 4 data shows greater IOP reduction with cataract surgery vs. surgery alone. Read more here.
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
This is the newest page. Registered accounts read further back.